Floatz logo

Mazdutide

Heart Failure With Mildly Reduced Ejection Fraction

Innovent Biologics (Suzhou) Co. Ltd.protein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Heart Failure With Mildly Reduced Ejection Fraction cohort.

Asset / SponsorPhaseRating
Empagliflozin
Jacob Moller
Phase 4BB
Finerenone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Semaglutide
University Medical Centre Ljubljana
Phase 2/3BB
Rivaroxaban
Janssen Research & Development, LLC
Phase 3B

View all 40 →

Same molecule, other indications

Mazdutide is also rated in:

obesity disorderDormant
BB
Indicative ·
70 / 100
View asset →
coronary artery disorderDormant
BB
Indicative ·
65 / 100
View asset →
sleep apnea syndromeDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →